VIGIL NEUROSCIENCE PRESENTS PRECLINICAL DATA ON VGL101 FOR ADULT-ONSET LEUKOENCEPHALOPATHY WITH AXONAL SPHEROIDS AND PIGMENTED GLIA (ALSP)

Update from Vigil Neuroscience “Findings from our preclinical studies evaluating TREM2 agonism continue to support the therapeutic potential of our lead clinical product candidate, VGL101 for the treatment of ALSP”.

To read the full press release: https://investors.vigilneuro.com/news-releases/news-release-details/vigil-neuroscience-presents-preclinical-data-vgl101-adult-onset